



ACTINOMYCIN D, C₂ AND VII, INHIBITORS OF GRB2-SHC INTERACTION PRODUCED BY STREPTOMYCES

Ji-Youn Nam, Hyae-Kyeong Kim, Kwang-Hee Son, Sung-Uk Kim, Byoung-Mog Kwon*

Mi Young Han, Yong Je Chung^a and Song Hae Bok

Korea Research Institute of Bioscience and Biotechnology, KIST, P.O Box 115, Yusung, Taejon, 305-600 Korea ^aDepartment of Biochemistry, Chungbuk National University

Received 20 May 1998; accepted 23 June 1998

Abstract: Actinomycin D, C₂ and VII, cyclic peptides, inhibited Grb2 SH2 domain association (IC₅₀ 5-7 μM) with a phosphotyrosine containing peptide derived from the Shc protein (pTyr317). Actinomycins are the first examples of nonphosphorylated natural ligands of SH2 domain.© 1998 Elsevier Science Ltd. All rights reserved.

Growth factor receptor-bound protein 2 (Grb2) and Src homologous and collagen (Shc) protein are adaptor proteins containing a Src homology 2 (SH2) domain that mediate the interaction with growth factor receptors or adaptor proteins by binding to specific phosphotyrosine motifs. Grb2 associates with phosphotyrosine sites of the activated receptors or Shc via their SH2 domain to link receptor tyrosine kinases to Ras signaling. This process of activation can lead to run away cell proliferation, differentiation and apoptosis in many kinds of cell types, resulting in diseases including cancer. Thus, blocking of the Grb2-Shc complexes may be lead to intervene the oncogenic signal transduction pathways and to develop a new antitumor drug.

In the course of screening for Grb2-Shc interaction inhibitors of microbial origin, we have isolated actinomycin C_2 and VII from *Streptomyces* sp. A1525.³ Actinomycins are a group of peptide antibiotics produced by various species of *Streptomyces*. The increasing interest in these natural compounds has been due to the biological significance of their action: they bind noncovalently to DNA and strongly inhibit the transcription of DNA to RNA.⁴ Therefore, actinomycins have become a powerful tool in biochemistry, molecular and cell biology. The whole broth (8 liters) of *Streptomyces* sp. A1525 was extracted with BuOH (8 liters x 2) to afford a crude extract (2.4g). The extract was applied on chromatography (C18, SiO₂, and HPLC) to give actinomycin D (1.5 mg/L), C_2 (10 mg/L), and VII. (8 mg/L). Active compounds were isolated by the monitoring of binding affinity against GST-Grb2 SH2 domain. Their UV spectrum data show the presence of chromophore, actinocin (λ_{max} in CH₃OH at 220 and 420nm). The molecular formulas of the inhibitors were determined as $C_{62}H_{86}N_{12}O_{16}$, $C_{63}H_{88}N_{12}O_{16}$ and $C_{64}H_{90}N_{12}O_{16}$, respectively by

HRFAB-MS. The actinomycin analogues were identified as the known actinomycin D, C₂, and VII according to the spectroscopic data.³

$$O=C \xrightarrow{H_3} C \xrightarrow{H_2} C C \xrightarrow{H_2} C C \xrightarrow{H_2} C \xrightarrow{H_2} C C \xrightarrow{H_2} C \xrightarrow{H_2} C C \xrightarrow{H_2}$$

The binding affinity of actinomycins to the Grb2 SH2 domain was measured in the presence of various concentrations (from 0.62 μ M to 39.8 μ M) of actinomycins. Actinomycin D, C₂, and VII inhibited the binding between GST-Grb2 SH2 domain and [H³]-labeled-phosphopeptide (Ac-SpYVNK-NH-C(O)-CH₂CH₂H³, derived from Shc pY317) with IC₅₀ values of 5.0 μ M, 5.9 μ M, and 7.6 μ M, respectively. And the displacement assay of Grb2 SH2 binding to labeled phosphopeptide were also performed with cold phosphopeptide (Ac-SpYVNVK-NH₂) to give IC₅₀ of 0.5 μ M.

Even though, a couple of peptide or peptidomimetic inhibitors were reported,⁶ actinomycins are the first inhibitors of the Grb2-Shc complex from natural sources. They will serve as useful compounds in understanding *ras* signal transduction pathways.

Acknowledgment This work was supported in part by grants from the Ministry of Health and Welfare (HMP-96-D-1031), and Ministry of Science and Technology (Star Project) in Korea. We kindly thank Dr. Jin-Keon Pai for his valuable suggestions on the assay system of Grb2-Shc interaction.

References

- 1. Pawson, T. Nature 1995, 373: 573.
- 2. Salcini, A. E., McGlade, J., Pelicci, G., Nicoletti, I., Pawson, T., Pelicci, P. G. Oncogene 1994, 9, 2827.
- 3. Betzel, C.; Rachev, R.; Dolashka, P.; Genov, N. Biochemica et Biophysica Acta 1993,1161, 47.
- 4. Wadkins, R. M.; Jares-E., E. A.; Klement, R.; Rudiger, A.; Jovin, T. M. J. Mol. Biol. 1996, 262, 53.
- 5. Koh, W. S.; Yoon, S. Y.; Lee, E. K.; Kwon, B. M.; Kim, J. W.; Han, M. Y. Cancer Letters 1997, 120, 1 and we also used the protein A-SPA bead (purchased from Amersham Life Science Ltd.).
- Oligino, L.; Lung, F. T.; Sastry, L.; Bigelow, J.; Cao, T.; Curran, M.; Burke, Jr. T. R.; Wang, S.; Krag, D.; Roller, P. P.; King, C. R. J. Biol. Chem. 1997, 272, 29046.